AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03139240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg oral
Description: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Study NCT03139240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given in addition to standard of care medications in women undergoing medical abortion
Study NCT03033524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001
Description: Calculated amount of drug will be diluted with normal saline and administered intravenously.
Study NCT00557843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
Study NCT02007668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
Study NCT00084799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody hu3S193
Study NCT01660477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT01660477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: oral
Study NCT06678958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction of acetabular defect by trabecular metal augment
Description: The augments were used in the flying buttress position
Study NCT02776527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
Study NCT05995379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA
Description: Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed.
Study NCT03658304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
Study NCT01795235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Saline s.c.
Study NCT01795235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glucagon
Description: Glucagon s.c.
Study NCT01795235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Sugar Pill
Study NCT01795235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Description: Beta-1 receptor antagonist
Study NCT02501772 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupressure by ankle band
Study NCT02501772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupressure by ankle band
Study NCT04229160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive mapping (Cardioinsight® system)
Description: Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure
Study NCT04229160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term cardiac monitoring (LINQ system)
Description: long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure
Study NCT04229160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation ablation procedure
Description: Atrial Fibrillation ablation procedure is done with standard practice
Study NCT00476593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design.
Study NCT00476593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design.
Study NCT02938013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]
Description: antiviral therapy for HCV
Study NCT02938013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir/Velpatasvir (SOF/VEL)
Description: antiviral therapy for HCV
Study NCT03019562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
Study NCT03019562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
Study NCT00856622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i. Fixed combination of latanoprost 0.005% and timolol 0.5%
Description: one drop in the morning and placebo in the evening
Study NCT00856622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5% ophthalmic solution
Description: one drop in the morning and evening
Study NCT00856622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: placebo in the morning and latanoprost .005% in the evening
Study NCT04219358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Gel Base
Description: Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water.
Study NCT04219358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% gel
Description: Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%.
Study NCT04219358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 0,05% gel
Description: Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form.
Study NCT04219358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod nanoencapsulated 0,05% gel
Description: Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%
Study NCT04219358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lip sunscreen 30 Sun Protector Factor (SPF)
Description: Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
Study NCT04219358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lip sunscreen 30 Sun Protector Factor (SPF)
Description: Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
Study NCT04219358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol
Description: Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon.~Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair.
Study NCT04219358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexpanthenol
Description: Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon.~Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair.
Study NCT02048696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary prevention and cardiac rehabilitation clinic
Description: Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
Study NCT03761693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting test
Description: The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~* blood glucose concentration drops \< 3.6 mmol/L;~* the child shows symptoms/signs of a low blood glucose concentration;~* patients parent(s) or guardian(s) request end of fast.
Study NCT06033313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negatively Framed text messages
Description: Negatively Framed text messages delivered to participants three times per week for 8 weeks.
Study NCT06033313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Framed text messages
Description: Positively Framed text messages delivered to participants three times per week for 8 weeks.
Study NCT03638596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Incentive provided for changing alcohol drinking patterns based on ankle monitor
Study NCT03638596 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
Study NCT01310361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT01310361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Benzathin Penicillin G
Description: It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
Study NCT02431624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTDS
Study NCT02431624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTDS
Study NCT04654936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND diet
Description: 12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
Study NCT01204125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study NCT01204125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR2405550 -BSI-201)
Description: Pharmaceutical form : solution for infusion~Route of administration :Intravenous
Study NCT00997477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foradil Combi (Formoterol-budesonide)
Study NCT01267916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 6 + 0
Description: Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
Study NCT01267916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 10 + 0
Description: Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
Study NCT01267916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 16 + 0
Description: Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
Study NCT01267916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 6 + 5
Description: Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
Study NCT01267916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 10 + 5
Description: Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
Study NCT01267916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RR 16 + 5
Description: Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
Study NCT06030115 — intervention group
Intervention type: OTHER
Intervention: Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)
Description: Data collected on participants who completed the intensity recovery progression protocol program
Study NCT00645151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Study NCT00263627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch pollen allergoid
Description: Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
Study NCT02540226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tranexamic acid
Study NCT02540226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Study NCT02540226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous saline
Study NCT02540226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical saline
Study NCT00004195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eniluracil
Description: Will be given to either subject pre-operative and metastatic disease
Study NCT00004195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: eniluracil
Description: Will be given to either subject pre-operative and metastatic disease
Study NCT00004195 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional colon surgery
Description: Only if the subject is amenable to surgical resections
Study NCT00004195 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional colon surgery
Description: Only if the subject is amenable to surgical resections
Study NCT02015585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interocclusal appliance
Description: Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
Study NCT02015585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Relining of the complete dentures
Description: Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
Study NCT02015585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete denture rehabilitation
Description: All patients will be rehabilitated with new complete dentures in the study
Study NCT02015585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete denture rehabilitation
Description: All patients will be rehabilitated with new complete dentures in the study
Study NCT03714802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Szabo T-Stenting Technique
Description: 2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
Study NCT03714802 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Szabo T-Stenting Technique
Description: 2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
Study NCT03714802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-Stenting Technique
Description: 2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
Study NCT03714802 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: T-Stenting Technique
Description: 2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
Study NCT04654936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND diet with no support
Description: Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
Study NCT04705857 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene
Description: gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
Study NCT04585035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
Study NCT03230591 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: LV vortex flow in Echocardiography
Study NCT03563053 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EryDex System
Description: EryDex System was a combination product that was used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which was infused into the patients.~EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg (mean ± standard deviation) of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T.~The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study, based on the analysis of the ATTeST blinded, Phase 3 study data.
Study NCT03519373 — intervention group
Intervention type: BIOLOGICAL
Intervention: TDaP
Description: Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
Study NCT03788369 — intervention group
Intervention type: PROCEDURE
Intervention: Hybrid Coronary Revascularization
Description: Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
Study NCT03722446 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Arrow Catheter Kit.
Description: The group will be randomized to receive this labor analgesia kit.
Study NCT03722446 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: B.Braun Catheter Kit
Description: The group will be randomized to receive this labor analgesia kit.
Study NCT04585035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
Description: Standard treatment of solid tumor, NSCLC or CRC
Study NCT02758626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ataluren
Description: Powder formulation